Breakdown of the Blood-Ocular Barrier as a Strategy for the Systemic Use of Nanosystems
Open Access
- 14 May 2012
- journal article
- other
- Published by MDPI AG in Pharmaceutics
- Vol. 4 (2) , 252-275
Abstract
Several drug delivery systems have been proposed to overcome physiological barriers, improving ocular bioavailability. Systemic routes are seldom used due to the blood-ocular barrier. Novel drug delivery systems based on nanotechnology techniques have been developed to overcome ocular physiological barriers. This non-systematic review suggests the utilization of a transitory blood-ocular breakdown to allow the access of drugs by nanotechnology drug delivery systems via the systemic route. We discuss the possible ways to cause the breakdown of the blood-ocular barrier: acute inflammation caused by intraocular surgery, induced ocular hypotony, and the use of inflammatory mediators. The suitability of use of the systemic route and its toxic effects are also discussed in this article.Keywords
This publication has 124 references indexed in Scilit:
- Reduction of atherosclerotic lesions in rabbits treated with etoposide associated with cholesterol-rich nanoemulsionsInternational Journal of Nanomedicine, 2011
- Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic reviewPatient Preference and Adherence, 2011
- Toxicological Studies on Silver Nanoparticles: Challenges and Opportunities in Assessment, Monitoring and ImagingNanomedicine, 2011
- Experimental Considerations on The Cytotoxicity of NanoparticlesNanomedicine, 2011
- Sub-Tenon's anaesthesia: complications and their preventionEye, 2011
- Effects of Common Topical Antiglaucoma Medications on the Ocular Surface, Eyelids and Periorbital TissueDrugs & Aging, 2011
- TNFα Is Required for Late BRB Breakdown in Diabetic Retinopathy, and Its Inhibition Prevents Leukostasis and Protects Vessels and Neurons from ApoptosisInvestigative Ophthalmology & Visual Science, 2011
- Drug delivery to the posterior segment of the eye for pharmacologic therapyExpert Review of Ophthalmology, 2010
- Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNVGene Therapy, 2009
- MRI in ocular drug deliveryNMR in Biomedicine, 2008